Olema Pharmaceuticals (OLMA) Stock Forecast & Price Target

Olema Pharmaceuticals is supported by a differentiated clinical strategy centered on palazestrant, whose OPERA-01 Phase 3 design targets both ESR1m and ESR1wt populations, a structure that could validate the CERAN thesis in a setting where prior oral SERDs have not shown ESR1wt benefit. The completion of enrollment in OPERA-01 and the palazestrant + atirmociclib study reduces execution risk, while the 2Q26 update showed Inluriyo sales of $75M and $110M YTD through June, underscoring real market demand and payer acceptance in ESR1m disease. OP-3136 further strengthens the story with 32 patients enrolled, 68% tumor shrinkage among 19 evaluable patients, 3 PRs, no DLTs, and sustained ~70-90% H3K23 reductions, suggesting a potentially valuable second asset and broader combination optionality.

Olema Pharmaceuticals is a clinical-stage biotech with no approved products, so its value depends heavily on future trial success rather than current operating performance, which heightens execution risk. The company posted 2Q26 EPS of ($0.61) and $67.2M in operating expenses, with costs expected to keep rising as OPERA-01, OPERA-02, and OP-3136 advance, while topline OPERA-01 data has already been delayed and palazestrant commercialization is now modeled for 2028 instead of 2027. Although $461.1M in cash at 2Q26 may fund operations into 2028, the need for roughly $400M more financing through 2040, combined with safety, efficacy, regulatory, and competition risks, supports a negative outlook.